<?xml version="1.0" encoding="UTF-8" ?> 

<rss version="2.0"> 
<channel> 
<title>Pharmacokinetics News</title> 
<link>http://www.mdlinx.com/PharmacistLinx/news.cfm/newspage/1/spec_id/24/subspec_id/277</link> 
<description>Pharmacokinetics</description> 
<language>en-us</language> 
<copyright>Copyright 2009 MDLinx, Inc.</copyright>










 



<item> 
<title><![CDATA[Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes]]></title> 
<link>http://www.mdlinx.com/PharmacistLinx/xml-article.cfm/2942320</link> 
<pubDate>11/9/2009</pubDate> 
<description><![CDATA[<b>Diabetic Medicine</b>]]></description> 
<guid>http://www.mdlinx.com/PharmacistLinx/xml-article.cfm/2942320</guid>
</item> 


 

<item> 
<title><![CDATA[Mechanistic Insight from In Silico Pharmacokinetic Experiments: Roles of P-glycoprotein, CYP3A4 Enzymes, and Microenvironments]]></title> 
<link>http://www.mdlinx.com/PharmacistLinx/xml-article.cfm/2931938</link> 
<pubDate>11/9/2009</pubDate> 
<description><![CDATA[<b>Journal of Pharmacology and Experimental Therapeutics</b>]]></description> 
<guid>http://www.mdlinx.com/PharmacistLinx/xml-article.cfm/2931938</guid>
</item> 
 
 


  


</channel> 
</rss>

